Sana Biotechnology (NASDAQ:SANA) Reaches New 12-Month Low – Should You Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price hit a new 52-week low during trading on Thursday . The stock traded as low as $2.29 and last traded at $2.30, with a volume of 1630882 shares trading hands. The stock had previously closed at $2.61.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SANA. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Citigroup lifted their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Sana Biotechnology in a research note on Wednesday, November 27th.

Sana Biotechnology Stock Down 12.1 %

The stock has a 50 day simple moving average of $3.43 and a 200 day simple moving average of $4.98. The stock has a market cap of $512.40 million, a price-to-earnings ratio of -1.73 and a beta of 1.33.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. Equities analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Insider Activity at Sana Biotechnology

In other news, Director Richard Mulligan sold 150,000 shares of the stock in a transaction that occurred on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the sale, the director now directly owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. This represents a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 31.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of SANA. Wilmington Savings Fund Society FSB bought a new stake in shares of Sana Biotechnology in the 3rd quarter worth $29,000. Stifel Financial Corp bought a new stake in Sana Biotechnology in the 3rd quarter worth about $43,000. EP Wealth Advisors LLC purchased a new stake in Sana Biotechnology in the 3rd quarter valued at about $45,000. Blue Trust Inc. increased its stake in Sana Biotechnology by 1,246.6% in the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after buying an additional 12,154 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $67,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.